Mallinckrodt, Silence Theraputics to commercialise RNAi therapeutics

Silence Theraputics and Mallinckrodt have announced a collaboration that will allow the companies to develop and commercialise RNAi drug targets designed to inhibit or ‘silence’ the complement cascade, a group of proteins that are involved in the immune system and that play a role in the development of inflammation.
Read more...

;